| scholarly article | Q13442814 |
| P50 | author | Jeong-Ju Yoo | Q85278010 |
| Fabien Zoulim | Q33116701 | ||
| Jung-Hwan Yoon | Q39903625 | ||
| P2093 | author name string | Hwi Young Kim | |
| Goh Eun Chung | |||
| Yoon Jun Kim | |||
| Dong Hyeon Lee | |||
| Jeong-Hoon Lee | |||
| Su Jong Yu | |||
| Eun Ju Cho | |||
| Yuri Cho | |||
| Minjong Lee | |||
| P2860 | cites work | Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B | Q82240888 |
| Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma | Q84441185 | ||
| KASL clinical practice guidelines: management of chronic hepatitis B | Q26752475 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Chronic hepatitis B: update 2009 | Q29617409 | ||
| Low dynamic state of viral competition in a chronic avian hepadnavirus infection | Q33787127 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients | Q35677233 | ||
| Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update | Q35706189 | ||
| Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. | Q36757579 | ||
| Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management | Q36863124 | ||
| Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. | Q37643680 | ||
| An update on vitamin D and human immunity | Q37945341 | ||
| Management of treatment failure in chronic hepatitis B. | Q37980893 | ||
| In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents | Q40115548 | ||
| Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus | Q40262602 | ||
| Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. | Q41175515 | ||
| Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load | Q41240306 | ||
| Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy | Q42218222 | ||
| Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues | Q43226767 | ||
| Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy | Q45414035 | ||
| Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. | Q46217486 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | tenofovir | Q155954 |
| chronic hepatitis B | Q55779876 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 66-73 | |
| P577 | publication date | 2017-02-14 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients | |
| P478 | volume | 23 |
| Q47260781 | Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray |
| Q60952819 | Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients? |
| Q41931198 | Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? |
| Q64897844 | KASL clinical practice guidelines for management of chronic hepatitis B. |
| Q58596648 | Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate |
Search more.